TFE3 EMSA Probe Set
- Known as:
- TFE3 EMSA Probe Set
- Catalog number:
- AY1247P
- Product Quantity:
- 25 rxn
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- TFE3 EMSA Probe Set
Related genes to: TFE3 EMSA Probe Set
- Gene:
- TFE3 NIH gene
- Name:
- transcription factor binding to IGHM enhancer 3
- Previous symbol:
- -
- Synonyms:
- TFEA, bHLHe33
- Chromosome:
- Xp11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1990-10-16
- Date modifiied:
- 2016-10-05
Related products to: TFE3 EMSA Probe Set
(+) Control probe (DNA), biotinylated(+) Control probe (RNA), biotinylated(-) Control probe (DNA), biotinylated(-) Control probe (RNA), biotinylated0.2 mm, 30 cm Spacer Set
0.2 mm, 30 cm Spacer Set0.35 mm, 30 cm Spacer Set
0.35 mm, 30 cm Spacer Set0.5 mm, 30 cm Spacer Set
0.5 mm, 30 cm Spacer Set0.75 mm Dual Gel Cast Set
0.75 mm Dual Gel Cast Set0.75 mm Plate Set, RM
0.75 mm Plate Set, RM
0.75 mm Plate Set, RM
Related articles to: TFE3 EMSA Probe Set
- Renal cell neoplasms with FLCN mutations, classically seen in Birt-Hogg-Dubé (BHD) syndrome typically include oncocytoma, chromophobe RCC, and hybrid oncocytic/chromophobe tumors (HOCT). Recent studies have highlighted FLCN-mutated renal cell carcinomas (RCCs) with unclassified morphologies, raising diagnostic challenges. - Source: PubMed
Publication date: 2026/04/16
Ding Chien-Kuang CChan EmilyLotan Tamara LHang Jen-FanGreenland Nancy YStohr Bradley ASimko Jeffry PSirohi Deepika - We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients. - Source: PubMed
Publication date: 2026/04/18
Chen Alice PRosenberger Christina LMoore NancyFoster Jared CNaqash Abdul RafehSharon EladO'Sullivan Coyne GeraldineSchwartz Gary KRiedel Richard FGlod JohnHu James SConley Anthony PRead William LBurgess Melissa ADavis Elizabeth JMerriam PriscillaDeshpande Hari ALadle Brian HOkuno Scott HBeck Jill CChen James LFerry-Galow Katherine VFino Kristin KMiller Brandon LWilsker Deborah FBegum AsmaParchment Ralph EDoroshow James H - TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare subtype of renal carcinoma that may present diagnostic challenges in cytologic specimens, particularly when metastatic disease represents the initial clinical manifestation. We report the case of a 72-year-old man presenting with bulky cervical lymphadenopathy clinically suspicious for lymphoma. Intraoperative touch imprint cytology from a level V lymph node demonstrated numerous discohesive and clustered epithelioid cells with abundant clear to granular cytoplasm, prompting reconsideration of a lymphoid process and appropriate tissue triage for histologic evaluation. Subsequent immunohistochemistry showed strong nuclear TFE3 expression with positivity for renal lineage markers, and RNA-based next-generation sequencing confirmed an SFPQ::TFE3 gene fusion. Imaging performed after pathologic diagnosis revealed an unsuspected renal mass. This case highlights the importance of recognizing cytomorphologic features suggestive of metastatic renal cell carcinoma during intraoperative consultation and underscores the role of cytologic evaluation in guiding diagnostic workup and tissue management in patients presenting with cervical lymphadenopathy of unknown origin. - Source: PubMed
Publication date: 2026/04/18
Pusztaszeri Marc P - - Source: PubMed
Publication date: 2026/03/18
Wang ZilinChe FengHu XuWei XinyuanZeng Hao - To analyze the clinicopathological features of low-grade oncocytic tumor of the kidney (LOT) and to explore its cellular origin, immunohistochemical, and molecular characteristics. - Source: PubMed
Publication date: 2026/04/13
Zhao JingWang YajieHuang JianJin XuCai YanyanLu YifanJiang TaoGan Wenjuan